Drug intelligence / Profile preview

IMA950 + poly-ICLC

Development stage: Unknown
Lead developer: Immatics US, Inc.
Modality: Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

IMA950 + poly-ICLC is a peptide vaccine immunotherapy consisting of IMA950 (a multipeptide vaccine containing 9 HLA-A2-restricted peptides eluted from glioblastoma samples and 2 HLA class II-binding peptides) combined with poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose), which serves as an adjuvant. This combination is designed to stimulate the immune system to recognize and attack glioma cells by generating both CD4+ and CD8+ T-cell responses against tumor-associated antigens.

Other names: IMA950/poly-ICLCIMA950-poly-ICLCIMA-950-poly-ICLCIMA 950-poly-ICLCIMA950 plus poly-ICLCIMA-950 plus poly-ICLCIMA 950 plus poly-ICLC

Targets

TLR3 (Toll-like receptor 3)TCR (T cell antigen receptor complex)IFIH1 (MDA5)

Beyond the preview

Go deeper on IMA950 + poly-ICLC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMA950 + poly-ICLC.

Explore the full profile